drugset
drugset / Trial / NCT02265302

Safety, Tolerability, Biological Effects and Pharmacokinetics of BIIL 284 BS in Healthy Males

NCT02265302 ↗

Phase 1 Completed 95 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to obtain information about the safety and tolerability of BIIL 248 BS, to find the pharmacologically active dose range for the two formulations PSE 1% and WIF tablets by determination of the surrogate marker CD11b (= Mac-1) and to obtain preliminary pharmacokinetic data as well as first information on food effects after administration of the 75 mg WIF tablet in healthy male volunteers

Timeline

Start
1998-06
Primary completion
1998-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject AMELUBANT Small molecule 0.025 mg Oral
Subject AMELUBANT Small molecule 25 mg Oral
Subject AMELUBANT Small molecule 75 mg Oral
Subject AMELUBANT Small molecule 250 mg Oral
Subject AMELUBANT Small molecule 750 mg Oral

Indications

No indication recorded.